MedTrace Logo

Combination Letrozole and Clomiphene Citrate Versus Letrozole Alone

NCT06507332 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2024-07-18

No results posted yet for this study

Summary

Clomiphene citrate is a non-steroidal triphenylethylene derivative distantly related to diethylstilbestrol. It acts as a selective estrogen receptor modulator (SERM), similar to tamoxifen and raloxifene. All three drugs are competitive inhibitors of estrogen binding to estrogen receptors (ERs) and have mixed agonist and antagonist activity, depending upon the target tissue.

Letrozole is a potent, nonsteroidal, aromatase inhibitor, originally used for postmenopausal breast cancer therapy.

Conditions

  • Polycystic Ovary Syndrome

Interventions

DRUG

Letrozole 2.5mg

to assess and compare the efficacy of Combination of letrozole and clomiphene citrate versus letrozole alone for ovulation induction in women with polycystic ovary syndrome (PCOS)

Sponsors & Collaborators

  • Ain Shams University

    collaborator OTHER

  • Egymedicalpedia

    lead INDUSTRY

Principal Investigators

  • Dina Yahia, Professor · Department of Obstetrics & Gynecology,Ain Shams University

  • Al Hassan Mohammad Khedr, Lecturer · Department of Obstetrics & Gynecology,Ain Shams University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
35 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-01
Primary Completion
2024-09-01
Completion
2024-09-10

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06507332 on ClinicalTrials.gov